Dexcom Inc. Stock
€68.61
Your prediction
Financial data and news for DexCom
sharewise wants to provide you with the best news and tools for DexCom, so we directly link to the best financial data sources.
Financials
News
DexCom Stock: Earnings Beat and New Market Access Drive Bull Case
DexCom, Inc. (NASDAQ: DXCM) has once again demonstrated its formidable position in the continuous glucose monitoring (CGM) market, delivering outstanding first-quarter 2025 financial results that
DexCom (DXCM) Q2 Revenue Jumps 15%
DexCom (NASDAQ:DXCM) reported its second-quarter 2025 results on July 30, 2025, delivering an upbeat performance highlighted by a revenue beat and continued expansion in the key type 2 diabetes
Why This Beaten-Down Medical Device Stock Could Be Your Best Investment for the Next 5 Years
Medical device specialist DexCom (NASDAQ: DXCM) has encountered significant headwinds in the past year. The company's financial results haven't been quite up to the market's standards, and broader
Dexcom Unveils Season 4 Roster for Game-Changing NIL Program at Signing Day Camp Hosted by Mark Andrews
DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the launch of the fourth season of Dexcom U, the company’s one-of-a-kind NIL (Name, Image and Likeness) program
2 Stocks to Buy on the Dip and Hold for 10 Years
One of Warren Buffett's famous pieces of investing advice is to be greedy when others are fearful. One way to apply this wisdom is to look for companies that have lagged the market recently but
Dexcom Unveils New Report on Type 2 Diabetes Management in the U.S. at ADA 2025
DexCom, Inc., the global leader in glucose biosensing, today released its "Dexcom State of Type 2 Report: Access and Attitudes Across the United States" ahead of the 85th Scientific Sessions of the
Prediction: These 2 Stocks Will Beat the Market in the Next Decade
Investors typically want to beat the market over the long run. Though it's not an easy task, it certainly is possible with the right companies. Let's consider two corporations that could help you do
Dexcom Announces Promotion of Jake Leach to the Expanded Role of President and COO
DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose biosensing, today announced the promotion of Jake Leach to president, in addition to his current role as chief
Dexcom Launches First Nationwide Search for College Athletes With Diabetes to Join Season Four of Dexcom U
DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the return of Dexcom U – its one-of-a-kind Name, Image and Likeness program exclusively for college athletes
Dexcom G7 15 Day Receives FDA Clearance: the Longest Lasting Wearable and Most Accurate CGM System
DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the FDA has cleared the Dexcom G7 15 Day Continuous Glucose Monitoring System for people over the age of 18 with
Government of Saskatchewan Expands Public Coverage for Dexcom Continuous Glucose Monitoring Systems
As of today, the Government of Saskatchewan’s expanded public coverage for continuous glucose monitoring (CGM) systems comes into effect. Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time
Nasdaq Sell-Off: 2 Brilliant Stocks to Buy No Matter What the Market Does Next
Equity markets started 2025 pretty well, but things haven't been so rosy in the past couple of months. The tech-heavy Nasdaq Composite index is down by 8% since the beginning of the year as I write
Got $200? 2 Healthcare Stocks to Buy and Hold Forever
Healthcare is considered a defensive industry, since good medical care is needed regardless of economic or market conditions. Therefore many companies in this sector are somewhat insulated from the
DexCom (DXCM) Q4 2024 Earnings Call Transcript
Image source: The Motley Fool.
DexCom (NASDAQ: DXCM)Q4 2024 Earnings CallFeb 13, 2025, 4:30 p.m. ET
Operator
Source Fool.com
DexCom: Revenue Up, EPS Misses Mark
DexCom (NASDAQ:DXCM), known for its continuous glucose monitoring (CGM) systems, recently unveiled its Q4 2024 earnings report on Feb. 13, 2025. This release highlighted an 8% growth in revenue
Dexcom Reports Second Quarter 2025 Financial Results, Updates Full Year 2025 Guidance and Announces CEO Succession Plan
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2025.
Second Quarter 2025 Financial Highlights:
-
Revenue grew 15% year-over-year to
Dexcom Schedules Second Quarter 2025 Earnings Release and Conference Call for July 30, 2025 at 4:30 p.m. Eastern Time.
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2025 financial results after market close on Wednesday, July 30, 2025. Management will hold a conference call
Dexcom Reports First Quarter 2025 Financial Results and Announces $750 Million Share Repurchase Program
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2025.
First Quarter 2025 Financial Highlights:
-
Revenue grew 12% year-over-year to
Dexcom Schedules First Quarter 2025 Earnings Release and Conference Call for May 1, 2025 at 4:30 p.m. Eastern Time.
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2025 financial results after market close on Thursday, May 1, 2025. Management will hold a conference call to
Dexcom Appoints Jon Coleman as Chief Commercial Officer
DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume
Dexcom Report Unveiled at ATTD 2025 Reveals HCPs Favour Tech Over Medication for Future of Type 2 Care
DexCom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing, today announced the launch of its first multi-region report, the "Dexcom State of Type 2 Report: Access and Attitudes Across
Dexcom Appoints Renée Galá to Board of Directors
DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Renée Galá to its Board of Directors, effective March 6, 2025.
Ms. Galá is an accomplished
Dexcom Announces Upcoming Conference Presentation
DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the 46th Annual Raymond James Institutional Investors Conference on Tuesday, March 4th.
The
Dexcom Reports Fourth Quarter and Fiscal Year 2024 Financial Results
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2024.
Fourth Quarter 2024 Financial Highlights:
-
Revenue grew 8%